import type { Biomarker, TrialBiomarkerUsage, CutoffTrend, AssayInfo, GWASAssociation, OpenTargetLink, NewsUpdate } from '../types';

export const BIOMARKERS: Biomarker[] = [
  { id: 'pdl1', name: 'PD-L1', aliases: ['CD274', 'B7-H1'], category: 'Predictive', description: 'Programmed death-ligand 1, immune checkpoint protein expressed on tumor cells and immune cells.', geneSymbol: 'CD274', uniprotId: 'Q9NZQ7' },
  { id: 'tmb', name: 'TMB', aliases: ['Tumor Mutational Burden', 'TMB-H'], category: 'Predictive', description: 'Total number of somatic mutations per megabase of interrogated genomic sequence in a tumor specimen.', geneSymbol: 'N/A' },
  { id: 'msi', name: 'MSI', aliases: ['Microsatellite Instability', 'MSI-H', 'dMMR'], category: 'Predictive', description: 'Condition of genetic hypermutability due to impaired DNA mismatch repair.', geneSymbol: 'MLH1/MSH2/MSH6/PMS2' },
  { id: 'her2', name: 'HER2', aliases: ['ERBB2', 'neu'], category: 'Predictive', description: 'Human epidermal growth factor receptor 2, a proto-oncogene.', geneSymbol: 'ERBB2', uniprotId: 'P04626' },
  { id: 'egfr', name: 'EGFR', aliases: ['ErbB-1', 'HER1'], category: 'Predictive', description: 'Epidermal growth factor receptor, commonly mutated in NSCLC.', geneSymbol: 'EGFR', uniprotId: 'P00533' },
  { id: 'alk', name: 'ALK', aliases: ['ALK fusion', 'EML4-ALK'], category: 'Predictive', description: 'Anaplastic lymphoma kinase rearrangements, common in NSCLC.', geneSymbol: 'ALK', uniprotId: 'Q9UM73' },
  { id: 'brca', name: 'BRCA1/2', aliases: ['BRCA1', 'BRCA2', 'HRD'], category: 'Predictive', description: 'BRCA gene mutations associated with homologous recombination deficiency.', geneSymbol: 'BRCA1/BRCA2' },
  { id: 'kras', name: 'KRAS', aliases: ['KRAS G12C', 'KRAS G12D'], category: 'Predictive', description: 'Kirsten rat sarcoma viral oncogene homolog mutations.', geneSymbol: 'KRAS', uniprotId: 'P01116' },
  { id: 'braf', name: 'BRAF', aliases: ['BRAF V600E', 'BRAF V600K'], category: 'Predictive', description: 'B-Raf proto-oncogene serine/threonine kinase mutations.', geneSymbol: 'BRAF', uniprotId: 'P15056' },
  { id: 'ntrk', name: 'NTRK', aliases: ['NTRK fusion', 'TRK'], category: 'Predictive', description: 'Neurotrophic tyrosine receptor kinase gene fusions.', geneSymbol: 'NTRK1/2/3' },
  { id: 'ctdna', name: 'ctDNA', aliases: ['Circulating Tumor DNA', 'cfDNA'], category: 'Monitoring', description: 'Cell-free tumor DNA fragments in blood used for minimal residual disease detection.', geneSymbol: 'N/A' },
  { id: 'tils', name: 'TILs', aliases: ['Tumor-Infiltrating Lymphocytes', 'sTILs'], category: 'Prognostic', description: 'Immune cells present within the tumor microenvironment.' },
  { id: 'er', name: 'ER', aliases: ['Estrogen Receptor', 'ER+', 'ESR1'], category: 'Predictive', description: 'Estrogen receptor expression, key determinant for endocrine therapy selection in breast cancer.', geneSymbol: 'ESR1', uniprotId: 'P03372' },
  { id: 'pr', name: 'PR', aliases: ['Progesterone Receptor', 'PR+', 'PGR'], category: 'Predictive', description: 'Progesterone receptor expression, often co-assessed with ER for hormone receptor status.', geneSymbol: 'PGR', uniprotId: 'P06401' },
  { id: 'pik3ca', name: 'PIK3CA', aliases: ['PI3K', 'PIK3CA mutation'], category: 'Predictive', description: 'PIK3CA mutations activate PI3K/AKT pathway; targetable with alpelisib in HR+/HER2- breast cancer.', geneSymbol: 'PIK3CA', uniprotId: 'P42336' },
  { id: 'ki67', name: 'Ki-67', aliases: ['Ki67', 'MIB-1', 'Proliferation Index'], category: 'Prognostic', description: 'Nuclear protein marker of cell proliferation, used to classify breast cancer intrinsic subtypes.', geneSymbol: 'MKI67', uniprotId: 'P46013' },
];

export const TUMOR_TYPES = ['NSCLC', 'Breast Cancer', 'Melanoma', 'Colorectal Cancer', 'Urothelial Carcinoma', 'Head & Neck SCC', 'Gastric Cancer', 'Hepatocellular Carcinoma', 'Renal Cell Carcinoma', 'Ovarian Cancer', 'Endometrial Cancer', 'Prostate Cancer', 'Pancreatic Cancer', 'Cervical Cancer'];

export const TRIAL_USAGES: TrialBiomarkerUsage[] = [
  // PD-L1 trials
  { nctId: 'NCT02578680', trialTitle: 'KEYNOTE-189: Pembro + Chemo in 1L NSCLC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: '1', cutoffUnit: '% TPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Merck', status: 'Completed', startYear: 2016, endYear: 2023 },
  { nctId: 'NCT02775435', trialTitle: 'KEYNOTE-042: Pembro Monotherapy 1L NSCLC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: '50', cutoffUnit: '% TPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Merck', status: 'Completed', startYear: 2016, endYear: 2022 },
  { nctId: 'NCT02453282', trialTitle: 'KEYNOTE-024: Pembro vs Chemo in PD-L1 High NSCLC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: '50', cutoffUnit: '% TPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Merck', status: 'Completed', startYear: 2015, endYear: 2021 },
  { nctId: 'NCT02366143', trialTitle: 'CheckMate 227: Nivo+Ipi in 1L NSCLC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: '1', cutoffUnit: '% TC', cutoffOperator: '>=', assayName: '28-8 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: false, sponsor: 'Bristol-Myers Squibb', status: 'Completed', startYear: 2015, endYear: 2022 },
  { nctId: 'NCT02367781', trialTitle: 'IMpower150: Atezo+Bev+Chemo in 1L NSCLC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: '50', cutoffUnit: '% TC or 10% IC', cutoffOperator: '>=', assayName: 'SP142', assayManufacturer: 'Ventana/Roche', companionDiagnostic: true, sponsor: 'Roche', status: 'Completed', startYear: 2015, endYear: 2022 },
  { nctId: 'NCT03036488', trialTitle: 'KEYNOTE-355: Pembro+Chemo in 1L TNBC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'Breast Cancer', phase: 'Phase 3', cutoffValue: '10', cutoffUnit: 'CPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Merck', status: 'Completed', startYear: 2017, endYear: 2023 },
  { nctId: 'NCT02807636', trialTitle: 'IMpassion130: Atezo+nabPaclitaxel in 1L TNBC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'Breast Cancer', phase: 'Phase 3', cutoffValue: '1', cutoffUnit: '% IC', cutoffOperator: '>=', assayName: 'SP142', assayManufacturer: 'Ventana/Roche', companionDiagnostic: true, sponsor: 'Roche', status: 'Completed', startYear: 2016, endYear: 2022 },
  { nctId: 'NCT02853305', trialTitle: 'KEYNOTE-826: Pembro+Chemo in Cervical Cancer', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'Cervical Cancer', phase: 'Phase 3', cutoffValue: '1', cutoffUnit: 'CPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Merck', status: 'Completed', startYear: 2017, endYear: 2023 },
  { nctId: 'NCT03189706', trialTitle: 'CheckMate 649: Nivo+Chemo in Gastric Cancer', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'Gastric Cancer', phase: 'Phase 3', cutoffValue: '5', cutoffUnit: 'CPS', cutoffOperator: '>=', assayName: '28-8 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: false, sponsor: 'Bristol-Myers Squibb', status: 'Completed', startYear: 2017, endYear: 2023 },
  { nctId: 'NCT02358031', trialTitle: 'CheckMate 274: Nivo Adjuvant Urothelial', biomarkerName: 'PD-L1', setting: 'Adjuvant', tumorType: 'Urothelial Carcinoma', phase: 'Phase 3', cutoffValue: '1', cutoffUnit: '% TC', cutoffOperator: '>=', assayName: '28-8 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: false, sponsor: 'Bristol-Myers Squibb', status: 'Completed', startYear: 2015, endYear: 2022 },
  { nctId: 'NCT03432871', trialTitle: 'KEYNOTE-966: Pembro+GemCis in BTC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'Hepatocellular Carcinoma', phase: 'Phase 3', cutoffValue: '1', cutoffUnit: 'CPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: false, sponsor: 'Merck', status: 'Completed', startYear: 2018, endYear: 2024 },

  // TMB trials
  { nctId: 'NCT02628067', trialTitle: 'KEYNOTE-158: Pembro in TMB-H Solid Tumors', biomarkerName: 'TMB', setting: '2L', tumorType: 'NSCLC', phase: 'Phase 2', cutoffValue: '10', cutoffUnit: 'mut/Mb', cutoffOperator: '>=', assayName: 'FoundationOne CDx', assayManufacturer: 'Foundation Medicine', companionDiagnostic: true, sponsor: 'Merck', status: 'Completed', startYear: 2016, endYear: 2022 },
  { nctId: 'NCT02848651', trialTitle: 'B-F1RST: Atezo 1L NSCLC by bTMB', biomarkerName: 'TMB', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 2', cutoffValue: '16', cutoffUnit: 'mut/Mb (blood)', cutoffOperator: '>=', assayName: 'FoundationOne Liquid CDx', assayManufacturer: 'Foundation Medicine', companionDiagnostic: false, sponsor: 'Roche', status: 'Completed', startYear: 2016, endYear: 2021 },
  { nctId: 'NCT02366143', trialTitle: 'CheckMate 227: Nivo+Ipi by TMB in NSCLC', biomarkerName: 'TMB', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: '10', cutoffUnit: 'mut/Mb', cutoffOperator: '>=', assayName: 'FoundationOne CDx', assayManufacturer: 'Foundation Medicine', companionDiagnostic: false, sponsor: 'Bristol-Myers Squibb', status: 'Completed', startYear: 2015, endYear: 2022 },
  { nctId: 'NCT03999437', trialTitle: 'NEPTUNE: Durva+Treme by bTMB in NSCLC', biomarkerName: 'TMB', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: '20', cutoffUnit: 'mut/Mb (blood)', cutoffOperator: '>=', assayName: 'GuardantOMNI', assayManufacturer: 'Guardant Health', companionDiagnostic: false, sponsor: 'AstraZeneca', status: 'Completed', startYear: 2018, endYear: 2023 },

  // MSI/dMMR trials
  { nctId: 'NCT02628067', trialTitle: 'KEYNOTE-158: Pembro in MSI-H Solid Tumors', biomarkerName: 'MSI', setting: '2L', tumorType: 'Colorectal Cancer', phase: 'Phase 2', cutoffValue: 'MSI-H', cutoffUnit: 'status', cutoffOperator: 'positive', assayName: 'PCR + IHC', assayManufacturer: 'Various', companionDiagnostic: true, sponsor: 'Merck', status: 'Completed', startYear: 2016, endYear: 2022 },
  { nctId: 'NCT02563002', trialTitle: 'KEYNOTE-177: Pembro 1L MSI-H CRC', biomarkerName: 'MSI', setting: '1L', tumorType: 'Colorectal Cancer', phase: 'Phase 3', cutoffValue: 'MSI-H/dMMR', cutoffUnit: 'status', cutoffOperator: 'positive', assayName: 'MSI by PCR + IHC for MMR', assayManufacturer: 'Promega/Ventana', companionDiagnostic: true, sponsor: 'Merck', status: 'Completed', startYear: 2016, endYear: 2023 },
  { nctId: 'NCT04008030', trialTitle: 'CheckMate 8HW: Nivo+Ipi in MSI-H/dMMR mCRC', biomarkerName: 'MSI', setting: '1L', tumorType: 'Colorectal Cancer', phase: 'Phase 3', cutoffValue: 'MSI-H/dMMR', cutoffUnit: 'status', cutoffOperator: 'positive', assayName: 'Local MSI/IHC testing', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'Bristol-Myers Squibb', status: 'Completed', startYear: 2019, endYear: 2025 },
  { nctId: 'NCT04118114', trialTitle: 'KEYNOTE-585: Pembro Neoadjuvant Gastric MSI', biomarkerName: 'MSI', setting: 'Neoadjuvant', tumorType: 'Gastric Cancer', phase: 'Phase 3', cutoffValue: 'MSI-H', cutoffUnit: 'status', cutoffOperator: 'positive', assayName: '22C3 + MSI PCR', assayManufacturer: 'Dako + Promega', companionDiagnostic: false, sponsor: 'Merck', status: 'Completed', startYear: 2019, endYear: 2024 },

  // HER2 trials
  { nctId: 'NCT03529110', trialTitle: 'DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ BC', biomarkerName: 'HER2', setting: '2L', tumorType: 'Breast Cancer', phase: 'Phase 3', cutoffValue: '3+', cutoffUnit: 'IHC or FISH+', cutoffOperator: 'positive', assayName: 'HercepTest / FISH', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Daiichi Sankyo / AstraZeneca', status: 'Completed', startYear: 2019, endYear: 2024 },
  { nctId: 'NCT03734029', trialTitle: 'DESTINY-Breast04: T-DXd in HER2-low BC', biomarkerName: 'HER2', setting: '3L+', tumorType: 'Breast Cancer', phase: 'Phase 3', cutoffValue: '1+ or 2+/FISH-', cutoffUnit: 'IHC (HER2-low)', cutoffOperator: '>=', assayName: 'HercepTest + FISH', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Daiichi Sankyo / AstraZeneca', status: 'Completed', startYear: 2019, endYear: 2024 },
  { nctId: 'NCT04014075', trialTitle: 'DESTINY-Gastric01: T-DXd in HER2+ Gastric', biomarkerName: 'HER2', setting: '3L+', tumorType: 'Gastric Cancer', phase: 'Phase 2', cutoffValue: '2+ or 3+', cutoffUnit: 'IHC', cutoffOperator: '>=', assayName: 'HercepTest', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Daiichi Sankyo / AstraZeneca', status: 'Completed', startYear: 2019, endYear: 2023 },
  { nctId: 'NCT04379596', trialTitle: 'DESTINY-Lung02: T-DXd in HER2+ NSCLC', biomarkerName: 'HER2', setting: '2L', tumorType: 'NSCLC', phase: 'Phase 2', cutoffValue: '2+ or 3+', cutoffUnit: 'IHC', cutoffOperator: '>=', assayName: 'HercepTest', assayManufacturer: 'Dako/Agilent', companionDiagnostic: false, sponsor: 'Daiichi Sankyo / AstraZeneca', status: 'Completed', startYear: 2020, endYear: 2024 },

  // EGFR trials
  { nctId: 'NCT02296125', trialTitle: 'FLAURA: Osimertinib 1L EGFR+ NSCLC', biomarkerName: 'EGFR', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'Ex19del/L858R', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'cobas EGFR Mutation Test v2', assayManufacturer: 'Roche', companionDiagnostic: true, sponsor: 'AstraZeneca', status: 'Completed', startYear: 2015, endYear: 2022 },
  { nctId: 'NCT04035486', trialTitle: 'ADAURA: Osimertinib Adjuvant EGFR+ NSCLC', biomarkerName: 'EGFR', setting: 'Adjuvant', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'Ex19del/L858R', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'cobas EGFR Mutation Test v2', assayManufacturer: 'Roche', companionDiagnostic: true, sponsor: 'AstraZeneca', status: 'Completed', startYear: 2019, endYear: 2023 },
  { nctId: 'NCT04487080', trialTitle: 'MARIPOSA: Amivantamab+Lazertinib 1L EGFR+', biomarkerName: 'EGFR', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'Ex19del/L858R', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'Therascreen EGFR Plasma', assayManufacturer: 'Qiagen', companionDiagnostic: false, sponsor: 'Janssen', status: 'Completed', startYear: 2020, endYear: 2025 },

  // ALK trials
  { nctId: 'NCT02075840', trialTitle: 'ALEX: Alectinib vs Crizotinib 1L ALK+ NSCLC', biomarkerName: 'ALK', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'ALK rearrangement', cutoffUnit: 'fusion', cutoffOperator: 'positive', assayName: 'Ventana ALK (D5F3)', assayManufacturer: 'Ventana/Roche', companionDiagnostic: true, sponsor: 'Roche', status: 'Completed', startYear: 2015, endYear: 2021 },
  { nctId: 'NCT03052608', trialTitle: 'CROWN: Lorlatinib vs Crizotinib 1L ALK+ NSCLC', biomarkerName: 'ALK', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'ALK rearrangement', cutoffUnit: 'fusion', cutoffOperator: 'positive', assayName: 'Ventana ALK (D5F3) or FISH', assayManufacturer: 'Ventana/Roche or Abbott', companionDiagnostic: true, sponsor: 'Pfizer', status: 'Completed', startYear: 2017, endYear: 2024 },

  // BRCA trials
  { nctId: 'NCT02987543', trialTitle: 'OLYMPIA: Olaparib Adjuvant HER2- BC with gBRCA', biomarkerName: 'BRCA1/2', setting: 'Adjuvant', tumorType: 'Breast Cancer', phase: 'Phase 3', cutoffValue: 'gBRCA1/2 pathogenic', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'BRACAnalysis CDx', assayManufacturer: 'Myriad Genetics', companionDiagnostic: true, sponsor: 'AstraZeneca', status: 'Completed', startYear: 2017, endYear: 2024 },
  { nctId: 'NCT01874353', trialTitle: 'SOLO-1: Olaparib Maintenance in BRCA+ Ovarian', biomarkerName: 'BRCA1/2', setting: 'Maintenance', tumorType: 'Ovarian Cancer', phase: 'Phase 3', cutoffValue: 'BRCA1/2 pathogenic', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'BRACAnalysis CDx', assayManufacturer: 'Myriad Genetics', companionDiagnostic: true, sponsor: 'AstraZeneca', status: 'Completed', startYear: 2014, endYear: 2022 },
  { nctId: 'NCT02655016', trialTitle: 'PROfound: Olaparib in HRR-mutated mCRPC', biomarkerName: 'BRCA1/2', setting: '2L', tumorType: 'Prostate Cancer', phase: 'Phase 3', cutoffValue: 'BRCA/ATM/HRR', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'FoundationOne CDx', assayManufacturer: 'Foundation Medicine', companionDiagnostic: true, sponsor: 'AstraZeneca', status: 'Completed', startYear: 2017, endYear: 2023 },

  // KRAS trials
  { nctId: 'NCT04303780', trialTitle: 'CodeBreaK 200: Sotorasib vs Docetaxel KRAS G12C NSCLC', biomarkerName: 'KRAS', setting: '2L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'G12C', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'therascreen KRAS RGQ PCR', assayManufacturer: 'Qiagen', companionDiagnostic: true, sponsor: 'Amgen', status: 'Completed', startYear: 2020, endYear: 2024 },
  { nctId: 'NCT04685135', trialTitle: 'KRYSTAL-12: Adagrasib vs Docetaxel KRAS G12C NSCLC', biomarkerName: 'KRAS', setting: '2L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'G12C', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'FoundationOne CDx', assayManufacturer: 'Foundation Medicine', companionDiagnostic: true, sponsor: 'Mirati Therapeutics', status: 'Completed', startYear: 2021, endYear: 2025 },

  // BRAF trials
  { nctId: 'NCT01689519', trialTitle: 'coBRIM: Vemurafenib+Cobimetinib in BRAF V600 Melanoma', biomarkerName: 'BRAF', setting: '1L', tumorType: 'Melanoma', phase: 'Phase 3', cutoffValue: 'V600', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'cobas 4800 BRAF V600', assayManufacturer: 'Roche', companionDiagnostic: true, sponsor: 'Roche', status: 'Completed', startYear: 2013, endYear: 2019 },
  { nctId: 'NCT01584648', trialTitle: 'COMBI-d: Dabrafenib+Trametinib BRAF V600 Melanoma', biomarkerName: 'BRAF', setting: '1L', tumorType: 'Melanoma', phase: 'Phase 3', cutoffValue: 'V600E/K', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'THxID BRAF Kit', assayManufacturer: 'bioMérieux', companionDiagnostic: true, sponsor: 'Novartis/GSK', status: 'Completed', startYear: 2013, endYear: 2020 },
  { nctId: 'NCT02465060', trialTitle: 'BEACON CRC: Enco+Bini+Cetux BRAF V600E CRC', biomarkerName: 'BRAF', setting: '2L', tumorType: 'Colorectal Cancer', phase: 'Phase 3', cutoffValue: 'V600E', cutoffUnit: 'mutation', cutoffOperator: 'positive', assayName: 'Local BRAF testing', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'Pfizer/Array BioPharma', status: 'Completed', startYear: 2016, endYear: 2022 },

  // NTRK trials
  { nctId: 'NCT02122913', trialTitle: 'NAVIGATE: Larotrectinib in NTRK+ Solid Tumors', biomarkerName: 'NTRK', setting: '2L', tumorType: 'NSCLC', phase: 'Phase 2', cutoffValue: 'NTRK fusion', cutoffUnit: 'fusion', cutoffOperator: 'positive', assayName: 'FISH / NGS / IHC', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'Bayer', status: 'Completed', startYear: 2015, endYear: 2023 },

  // ctDNA trials
  { nctId: 'NCT04068103', trialTitle: 'CIRCULATE: ctDNA-guided Adjuvant CRC', biomarkerName: 'ctDNA', setting: 'Adjuvant', tumorType: 'Colorectal Cancer', phase: 'Phase 3', cutoffValue: 'ctDNA positive', cutoffUnit: 'detection', cutoffOperator: 'positive', assayName: 'Signatera', assayManufacturer: 'Natera', companionDiagnostic: false, sponsor: 'Multiple', status: 'Recruiting', startYear: 2020 },
  { nctId: 'NCT04585477', trialTitle: 'MERMAID-1: Durva Adjuvant by ctDNA in NSCLC', biomarkerName: 'ctDNA', setting: 'Adjuvant', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'ctDNA positive', cutoffUnit: 'detection', cutoffOperator: 'positive', assayName: 'Guardant Reveal', assayManufacturer: 'Guardant Health', companionDiagnostic: false, sponsor: 'AstraZeneca', status: 'Completed', startYear: 2020, endYear: 2025 },

  // TILs trials
  { nctId: 'NCT03645928', trialTitle: 'Lifileucel (TIL therapy) in Melanoma', biomarkerName: 'TILs', setting: '3L+', tumorType: 'Melanoma', phase: 'Phase 2', cutoffValue: 'TIL presence', cutoffUnit: 'presence', cutoffOperator: 'positive', assayName: 'H&E / CD3/CD8 IHC', assayManufacturer: 'Pathology lab', companionDiagnostic: false, sponsor: 'Iovance Biotherapeutics', status: 'Completed', startYear: 2018, endYear: 2024 },
];

export const CUTOFF_TRENDS: CutoffTrend[] = [
  // PD-L1 TPS cutoff trends in NSCLC
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2015, cutoffValue: 50, cutoffUnit: '% TPS', trialCount: 3, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2016, cutoffValue: 50, cutoffUnit: '% TPS', trialCount: 5, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2016, cutoffValue: 1, cutoffUnit: '% TPS', trialCount: 4, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2017, cutoffValue: 1, cutoffUnit: '% TPS', trialCount: 8, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2018, cutoffValue: 1, cutoffUnit: '% TPS', trialCount: 12, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2019, cutoffValue: 1, cutoffUnit: '% TPS', trialCount: 15, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2020, cutoffValue: 1, cutoffUnit: '% TPS', trialCount: 18, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2021, cutoffValue: 1, cutoffUnit: '% TPS', trialCount: 20, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2022, cutoffValue: 1, cutoffUnit: '% TPS', trialCount: 22, assay: '22C3 / SP263 / 28-8' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2023, cutoffValue: 1, cutoffUnit: '% TPS', trialCount: 25, assay: '22C3 / SP263 / 28-8' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2024, cutoffValue: 1, cutoffUnit: '% TPS', trialCount: 28, assay: 'Multiple harmonized' },
  { biomarkerName: 'PD-L1', tumorType: 'NSCLC', year: 2025, cutoffValue: 1, cutoffUnit: '% TPS', trialCount: 30, assay: 'Multiple harmonized' },

  // PD-L1 CPS cutoff trends
  { biomarkerName: 'PD-L1', tumorType: 'Breast Cancer', year: 2017, cutoffValue: 1, cutoffUnit: 'CPS', trialCount: 2, assay: 'SP142' },
  { biomarkerName: 'PD-L1', tumorType: 'Breast Cancer', year: 2018, cutoffValue: 10, cutoffUnit: 'CPS', trialCount: 3, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'Breast Cancer', year: 2019, cutoffValue: 10, cutoffUnit: 'CPS', trialCount: 5, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'Breast Cancer', year: 2020, cutoffValue: 10, cutoffUnit: 'CPS', trialCount: 7, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'Breast Cancer', year: 2021, cutoffValue: 10, cutoffUnit: 'CPS', trialCount: 9, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'Breast Cancer', year: 2022, cutoffValue: 10, cutoffUnit: 'CPS', trialCount: 11, assay: '22C3 pharmDx' },
  { biomarkerName: 'PD-L1', tumorType: 'Breast Cancer', year: 2023, cutoffValue: 10, cutoffUnit: 'CPS', trialCount: 13, assay: '22C3 pharmDx' },

  // TMB cutoff trends
  { biomarkerName: 'TMB', tumorType: 'NSCLC', year: 2016, cutoffValue: 10, cutoffUnit: 'mut/Mb', trialCount: 2, assay: 'FoundationOne CDx' },
  { biomarkerName: 'TMB', tumorType: 'NSCLC', year: 2017, cutoffValue: 10, cutoffUnit: 'mut/Mb', trialCount: 4, assay: 'FoundationOne CDx' },
  { biomarkerName: 'TMB', tumorType: 'NSCLC', year: 2018, cutoffValue: 10, cutoffUnit: 'mut/Mb', trialCount: 7, assay: 'FoundationOne CDx' },
  { biomarkerName: 'TMB', tumorType: 'NSCLC', year: 2019, cutoffValue: 10, cutoffUnit: 'mut/Mb', trialCount: 10, assay: 'FoundationOne CDx' },
  { biomarkerName: 'TMB', tumorType: 'NSCLC', year: 2020, cutoffValue: 10, cutoffUnit: 'mut/Mb', trialCount: 14, assay: 'FoundationOne CDx / TSO500' },
  { biomarkerName: 'TMB', tumorType: 'NSCLC', year: 2021, cutoffValue: 10, cutoffUnit: 'mut/Mb', trialCount: 16, assay: 'Multiple panels' },
  { biomarkerName: 'TMB', tumorType: 'NSCLC', year: 2022, cutoffValue: 10, cutoffUnit: 'mut/Mb', trialCount: 18, assay: 'Multiple panels' },
  { biomarkerName: 'TMB', tumorType: 'NSCLC', year: 2023, cutoffValue: 10, cutoffUnit: 'mut/Mb', trialCount: 20, assay: 'WES + Panel harmonized' },

  // HER2 trends
  { biomarkerName: 'HER2', tumorType: 'Breast Cancer', year: 2015, cutoffValue: 3, cutoffUnit: 'IHC score', trialCount: 8, assay: 'HercepTest' },
  { biomarkerName: 'HER2', tumorType: 'Breast Cancer', year: 2016, cutoffValue: 3, cutoffUnit: 'IHC score', trialCount: 10, assay: 'HercepTest' },
  { biomarkerName: 'HER2', tumorType: 'Breast Cancer', year: 2017, cutoffValue: 3, cutoffUnit: 'IHC score', trialCount: 12, assay: 'HercepTest' },
  { biomarkerName: 'HER2', tumorType: 'Breast Cancer', year: 2018, cutoffValue: 3, cutoffUnit: 'IHC score', trialCount: 13, assay: 'HercepTest' },
  { biomarkerName: 'HER2', tumorType: 'Breast Cancer', year: 2019, cutoffValue: 1, cutoffUnit: 'IHC score (HER2-low)', trialCount: 3, assay: 'HercepTest' },
  { biomarkerName: 'HER2', tumorType: 'Breast Cancer', year: 2020, cutoffValue: 1, cutoffUnit: 'IHC score (HER2-low)', trialCount: 5, assay: 'HercepTest' },
  { biomarkerName: 'HER2', tumorType: 'Breast Cancer', year: 2021, cutoffValue: 1, cutoffUnit: 'IHC score (HER2-low)', trialCount: 8, assay: 'HercepTest' },
  { biomarkerName: 'HER2', tumorType: 'Breast Cancer', year: 2022, cutoffValue: 1, cutoffUnit: 'IHC score (HER2-low)', trialCount: 12, assay: 'HercepTest' },
  { biomarkerName: 'HER2', tumorType: 'Breast Cancer', year: 2023, cutoffValue: 1, cutoffUnit: 'IHC score (HER2-low)', trialCount: 16, assay: 'HercepTest + quantitative HER2' },
  { biomarkerName: 'HER2', tumorType: 'Breast Cancer', year: 2024, cutoffValue: 0, cutoffUnit: 'IHC (HER2-ultralow)', trialCount: 5, assay: 'Quantitative IHC / AQUA' },
];

export const ASSAYS: AssayInfo[] = [
  { name: '22C3 pharmDx', manufacturer: 'Dako/Agilent', platform: 'IHC', antibodyClone: '22C3', fdaApproved: true, companionDiagnosticFor: ['Pembrolizumab (NSCLC, HNSCC, Urothelial, Gastric, Cervical, TNBC)'], biomarkers: ['PD-L1'] },
  { name: '28-8 pharmDx', manufacturer: 'Dako/Agilent', platform: 'IHC', antibodyClone: '28-8', fdaApproved: true, companionDiagnosticFor: ['Nivolumab (Melanoma, NSCLC)'], biomarkers: ['PD-L1'] },
  { name: 'SP142', manufacturer: 'Ventana/Roche', platform: 'IHC', antibodyClone: 'SP142', fdaApproved: true, companionDiagnosticFor: ['Atezolizumab (TNBC, NSCLC, Urothelial)'], biomarkers: ['PD-L1'] },
  { name: 'SP263', manufacturer: 'Ventana/Roche', platform: 'IHC', antibodyClone: 'SP263', fdaApproved: true, companionDiagnosticFor: ['Durvalumab (Urothelial)'], biomarkers: ['PD-L1'] },
  { name: '73-10', manufacturer: 'Dako/Agilent', platform: 'IHC', antibodyClone: '73-10', fdaApproved: true, companionDiagnosticFor: ['Cemiplimab (Cervical)'], biomarkers: ['PD-L1'] },
  { name: 'FoundationOne CDx', manufacturer: 'Foundation Medicine', platform: 'NGS (324 genes)', fdaApproved: true, companionDiagnosticFor: ['Multiple targeted therapies', 'TMB-H (Pembrolizumab)'], biomarkers: ['TMB', 'MSI', 'BRCA1/2', 'EGFR', 'ALK', 'KRAS', 'BRAF', 'NTRK'] },
  { name: 'FoundationOne Liquid CDx', manufacturer: 'Foundation Medicine', platform: 'ctDNA NGS', fdaApproved: true, companionDiagnosticFor: ['Blood-based TMB', 'EGFR', 'ALK', 'BRCA'], biomarkers: ['TMB', 'EGFR', 'ALK', 'BRCA1/2', 'ctDNA'] },
  { name: 'cobas EGFR Mutation Test v2', manufacturer: 'Roche', platform: 'PCR', fdaApproved: true, companionDiagnosticFor: ['Osimertinib', 'Erlotinib', 'Gefitinib'], biomarkers: ['EGFR'] },
  { name: 'Ventana ALK (D5F3)', manufacturer: 'Ventana/Roche', platform: 'IHC', antibodyClone: 'D5F3', fdaApproved: true, companionDiagnosticFor: ['Alectinib', 'Crizotinib', 'Ceritinib'], biomarkers: ['ALK'] },
  { name: 'BRACAnalysis CDx', manufacturer: 'Myriad Genetics', platform: 'PCR/Sequencing', fdaApproved: true, companionDiagnosticFor: ['Olaparib (Breast, Ovarian, Pancreatic, Prostate)', 'Rucaparib (Ovarian, Prostate)'], biomarkers: ['BRCA1/2'] },
  { name: 'HercepTest', manufacturer: 'Dako/Agilent', platform: 'IHC', antibodyClone: 'Various', fdaApproved: true, companionDiagnosticFor: ['Trastuzumab', 'T-DM1', 'T-DXd', 'Pertuzumab'], biomarkers: ['HER2'] },
  { name: 'therascreen KRAS RGQ PCR', manufacturer: 'Qiagen', platform: 'PCR', fdaApproved: true, companionDiagnosticFor: ['Sotorasib'], biomarkers: ['KRAS'] },
  { name: 'TSO500', manufacturer: 'Illumina', platform: 'NGS (523 genes)', fdaApproved: true, companionDiagnosticFor: ['TMB assessment'], biomarkers: ['TMB', 'MSI', 'EGFR', 'BRAF', 'KRAS', 'NTRK'] },
  { name: 'Signatera', manufacturer: 'Natera', platform: 'ctDNA (tumor-informed PCR)', fdaApproved: false, companionDiagnosticFor: [], biomarkers: ['ctDNA'] },
  { name: 'Guardant360 CDx', manufacturer: 'Guardant Health', platform: 'ctDNA NGS (74 genes)', fdaApproved: true, companionDiagnosticFor: ['Osimertinib (EGFR T790M)', 'Amivantamab (EGFR Exon20ins)'], biomarkers: ['EGFR', 'KRAS', 'ctDNA'] },
  { name: 'cobas 4800 BRAF V600', manufacturer: 'Roche', platform: 'PCR', fdaApproved: true, companionDiagnosticFor: ['Vemurafenib', 'Cobimetinib'], biomarkers: ['BRAF'] },
  { name: 'THxID BRAF Kit', manufacturer: 'bioMérieux', platform: 'PCR', fdaApproved: true, companionDiagnosticFor: ['Dabrafenib', 'Trametinib'], biomarkers: ['BRAF'] },
  { name: 'MSI by PCR (Promega)', manufacturer: 'Promega', platform: 'PCR (BAT-25, BAT-26, NR-21, NR-24, MONO-27)', fdaApproved: false, companionDiagnosticFor: [], biomarkers: ['MSI'] },
  { name: 'Guardant Reveal', manufacturer: 'Guardant Health', platform: 'ctDNA (methylation + SNV)', fdaApproved: false, companionDiagnosticFor: [], biomarkers: ['ctDNA'] },
];

export const GWAS_ASSOCIATIONS: GWASAssociation[] = [
  { rsId: 'rs2228145', gene: 'IL6R', traitName: 'C-reactive protein levels', pValue: 1e-30, oddsRatio: 1.12, riskAllele: 'C', population: 'European', pubmedId: '22286173', studyTitle: 'IL6R genotype and CRP levels in large cohort', biomarkerRelevance: 'CRP is a key inflammatory biomarker in I-O; IL6R variants modulate baseline inflammation affecting PD-L1 expression' },
  { rsId: 'rs4143815', gene: 'CD274 (PD-L1)', traitName: 'PD-L1 expression regulation', pValue: 2.5e-12, riskAllele: 'G', population: 'European', pubmedId: '29892050', studyTitle: 'Genetic determinants of PD-L1 expression', biomarkerRelevance: 'Direct genetic regulation of PD-L1 expression levels affecting immunotherapy response prediction' },
  { rsId: 'rs1800896', gene: 'IL10', traitName: 'Immune checkpoint response', pValue: 5e-8, oddsRatio: 1.3, riskAllele: 'A', population: 'Multi-ethnic', pubmedId: '30718856', studyTitle: 'IL-10 polymorphisms and immunotherapy outcomes', biomarkerRelevance: 'IL-10 variants influence tumor microenvironment immunosuppression, modulating TIL density and checkpoint inhibitor efficacy' },
  { rsId: 'rs2981578', gene: 'FGFR2', traitName: 'Breast cancer susceptibility', pValue: 1e-76, oddsRatio: 1.26, riskAllele: 'G', population: 'European', pubmedId: '17529967', studyTitle: 'FGFR2 breast cancer GWAS', biomarkerRelevance: 'FGFR2 variants associated with ER+ breast cancer risk; FGFR pathway alterations emerging as therapeutic biomarkers' },
  { rsId: 'rs11571833', gene: 'BRCA2', traitName: 'Breast and ovarian cancer risk', pValue: 2e-15, oddsRatio: 2.26, riskAllele: 'A', population: 'European', pubmedId: '23544012', studyTitle: 'BRCA2 GWAS and cancer predisposition', biomarkerRelevance: 'BRCA2 germline variants are FDA-approved companion diagnostic biomarkers for PARP inhibitors (Olaparib, Rucaparib)' },
  { rsId: 'rs1042522', gene: 'TP53', traitName: 'Multiple cancer susceptibility', pValue: 3e-10, oddsRatio: 1.15, riskAllele: 'C', population: 'Multi-ethnic', pubmedId: '21743471', studyTitle: 'TP53 polymorphism and cancer risk', biomarkerRelevance: 'TP53 mutations are the most common somatic alterations in cancer; affect TMB assessment and response to checkpoint inhibitors' },
  { rsId: 'rs10936599', gene: 'TERT', traitName: 'Telomere length / cancer risk', pValue: 6e-20, oddsRatio: 1.1, riskAllele: 'C', population: 'European', pubmedId: '23535732', studyTitle: 'TERT variants and cancer susceptibility', biomarkerRelevance: 'TERT promoter mutations are emerging biomarkers in bladder cancer and melanoma for prognosis assessment' },
  { rsId: 'rs55699039', gene: 'ERBB2 (HER2)', traitName: 'HER2 amplification predisposition', pValue: 1e-9, oddsRatio: 1.5, riskAllele: 'T', population: 'European', pubmedId: '25327703', studyTitle: 'Germline variants affecting HER2 amplification', biomarkerRelevance: 'Germline ERBB2 variants may predispose to HER2 amplification; directly relevant to HER2-targeted therapy eligibility' },
  { rsId: 'rs4444235', gene: 'BMP4', traitName: 'Colorectal cancer risk', pValue: 8.1e-10, oddsRatio: 1.1, riskAllele: 'C', population: 'European', pubmedId: '19011631', studyTitle: 'BMP pathway variants in CRC', biomarkerRelevance: 'BMP pathway germline variants influence CRC biology; relevant to MSI-H/dMMR biomarker testing strategies' },
  { rsId: 'rs2066844', gene: 'NOD2', traitName: 'Inflammatory bowel disease / CRC', pValue: 1e-12, oddsRatio: 2.2, riskAllele: 'T', population: 'European', pubmedId: '11385576', studyTitle: 'NOD2 and inflammatory disease', biomarkerRelevance: 'Chronic inflammation pathway; relevant to MSI testing in Lynch-associated and inflammation-driven CRC' },
];

export const OPEN_TARGET_LINKS: OpenTargetLink[] = [
  { targetId: 'ENSG00000120217', targetName: 'CD274 (PD-L1)', diseaseId: 'EFO_0000616', diseaseName: 'Non-small cell lung carcinoma', associationScore: 0.89, datatypeScores: { literature: 0.92, rna_expression: 0.75, genetic_association: 0.45, somatic_mutation: 0.3, known_drug: 0.95, animal_model: 0.6, affected_pathway: 0.7 } },
  { targetId: 'ENSG00000141736', targetName: 'ERBB2 (HER2)', diseaseId: 'EFO_0000305', diseaseName: 'Breast carcinoma', associationScore: 0.95, datatypeScores: { literature: 0.98, rna_expression: 0.85, genetic_association: 0.7, somatic_mutation: 0.8, known_drug: 0.99, animal_model: 0.75, affected_pathway: 0.9 } },
  { targetId: 'ENSG00000146648', targetName: 'EGFR', diseaseId: 'EFO_0000616', diseaseName: 'Non-small cell lung carcinoma', associationScore: 0.97, datatypeScores: { literature: 0.99, rna_expression: 0.8, genetic_association: 0.65, somatic_mutation: 0.95, known_drug: 0.98, animal_model: 0.7, affected_pathway: 0.85 } },
  { targetId: 'ENSG00000133703', targetName: 'KRAS', diseaseId: 'EFO_0000616', diseaseName: 'Non-small cell lung carcinoma', associationScore: 0.93, datatypeScores: { literature: 0.95, rna_expression: 0.6, genetic_association: 0.55, somatic_mutation: 0.98, known_drug: 0.85, animal_model: 0.65, affected_pathway: 0.92 } },
  { targetId: 'ENSG00000157764', targetName: 'BRAF', diseaseId: 'EFO_0000389', diseaseName: 'Melanoma', associationScore: 0.96, datatypeScores: { literature: 0.97, rna_expression: 0.7, genetic_association: 0.6, somatic_mutation: 0.99, known_drug: 0.97, animal_model: 0.72, affected_pathway: 0.88 } },
  { targetId: 'ENSG00000012048', targetName: 'BRCA1', diseaseId: 'EFO_0001075', diseaseName: 'Ovarian carcinoma', associationScore: 0.94, datatypeScores: { literature: 0.96, rna_expression: 0.65, genetic_association: 0.92, somatic_mutation: 0.7, known_drug: 0.9, animal_model: 0.68, affected_pathway: 0.85 } },
  { targetId: 'ENSG00000171094', targetName: 'ALK', diseaseId: 'EFO_0000616', diseaseName: 'Non-small cell lung carcinoma', associationScore: 0.91, datatypeScores: { literature: 0.93, rna_expression: 0.55, genetic_association: 0.4, somatic_mutation: 0.85, known_drug: 0.95, animal_model: 0.6, affected_pathway: 0.8 } },
  { targetId: 'ENSG00000133703', targetName: 'KRAS', diseaseId: 'EFO_0005842', diseaseName: 'Colorectal carcinoma', associationScore: 0.88, datatypeScores: { literature: 0.9, rna_expression: 0.5, genetic_association: 0.5, somatic_mutation: 0.95, known_drug: 0.7, animal_model: 0.6, affected_pathway: 0.88 } },
];

export const NEWS_UPDATES: NewsUpdate[] = [
  { id: 'n1', title: 'FDA Approves HER2-Ultralow Category for T-DXd Expanded Indication', source: 'FDA', date: '2025-12-15', summary: 'The FDA expanded the indication for trastuzumab deruxtecan to include patients with HER2-ultralow breast cancer (IHC 0 with faint staining), fundamentally redefining the HER2 testing paradigm.', url: '#', biomarkers: ['HER2'], tags: ['FDA Approval', 'Breast Cancer', 'Companion Diagnostic'] },
  { id: 'n2', title: 'ctDNA-Guided Adjuvant Therapy Validated in CIRCULATE Japan Results', source: 'ASCO', date: '2025-11-20', summary: 'Phase III data confirms ctDNA-guided approach reduces unnecessary adjuvant chemotherapy in stage II-III CRC by 50% while maintaining disease-free survival outcomes.', url: '#', biomarkers: ['ctDNA'], tags: ['Phase 3', 'CRC', 'MRD'] },
  { id: 'n3', title: 'TMB Cutoff Harmonization: Friends of Cancer Research Consensus Statement', source: 'PubMed', date: '2025-10-05', summary: 'Multi-stakeholder consortium publishes definitive guidelines on TMB measurement standardization across NGS panels, recommending 10 mut/Mb as universal threshold with panel-specific calibration.', url: '#', biomarkers: ['TMB'], tags: ['Standardization', 'NGS', 'Guidelines'] },
  { id: 'n4', title: 'KRAS G12D Inhibitors Show Promise: First Clinical Data from Phase I Trials', source: 'ESMO', date: '2025-09-18', summary: 'Multiple KRAS G12D inhibitors demonstrate preliminary efficacy in pancreatic and colorectal cancers, expanding the druggable KRAS landscape beyond G12C.', url: '#', biomarkers: ['KRAS'], tags: ['Phase 1', 'PDAC', 'CRC'] },
  { id: 'n5', title: 'PD-L1 CPS vs TPS: Meta-Analysis Favors CPS for Pan-Tumor Prediction', source: 'PubMed', date: '2025-08-22', summary: 'Comprehensive meta-analysis of 45 trials and 28,000 patients demonstrates CPS outperforms TPS in predicting immunotherapy benefit across solid tumor types.', url: '#', biomarkers: ['PD-L1'], tags: ['Meta-Analysis', 'Scoring', 'Pan-Tumor'] },
  { id: 'n6', title: 'GWAS Identifies Novel Loci Predicting Immunotherapy Hyperprogression', source: 'PubMed', date: '2025-07-14', summary: 'Large-scale GWAS of 15,000 immunotherapy-treated patients identifies 8 novel loci associated with hyperprogressive disease, with potential for pre-treatment risk stratification.', url: '#', biomarkers: ['PD-L1', 'TMB', 'TILs'], tags: ['GWAS', 'Pharmacogenomics', 'Safety'] },
  { id: 'n7', title: 'NTRK Testing Recommendations Updated: RNA-Based Assays Preferred', source: 'ESMO', date: '2025-06-30', summary: 'Updated ESMO guidelines recommend RNA-based NGS panels as preferred method for NTRK fusion detection, citing superior sensitivity over DNA-based approaches.', url: '#', biomarkers: ['NTRK'], tags: ['Guidelines', 'NGS', 'RNA'] },
  { id: 'n8', title: 'Open Targets Platform Launches Biomarker-Specific Module', source: 'PubMed', date: '2025-05-10', summary: 'Open Targets announces a dedicated biomarker module integrating clinical trial endpoint data with genetic evidence, enabling systematic biomarker-target-disease triangulation.', url: '#', biomarkers: ['EGFR', 'BRAF', 'KRAS', 'HER2'], tags: ['Open Source', 'Database', 'Integration'] },
  { id: 'n9', title: 'ALK Resistance Biomarkers: Compound Mutations Require Sequential Testing', source: 'PubMed', date: '2025-04-22', summary: 'Study demonstrates compound ALK mutations emerge in 35% of lorlatinib-resistant patients, necessitating sequential liquid biopsy monitoring as a resistance biomarker strategy.', url: '#', biomarkers: ['ALK', 'ctDNA'], tags: ['Resistance', 'Liquid Biopsy', 'NSCLC'] },
  { id: 'n10', title: 'MSI Testing Evolution: AI-Powered H&E Approaches Non-Inferior to PCR', source: 'PubMed', date: '2025-03-15', summary: 'Multi-center validation study shows AI-based MSI detection from H&E slides achieves 97% concordance with PCR-based testing, potentially eliminating need for molecular MSI testing.', url: '#', biomarkers: ['MSI'], tags: ['AI/ML', 'Pathology', 'Cost-Effectiveness'] },
];
